SCHEMBL5535582

SCHEMBL5535582

[O]c1ccc(N2CCC(Nc3ccccc3F)CC2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.53
KDM4E B2RXH2 2/20 0.53
ALDH1A1 P00352 5/20 0.43
POLB P06746 1/20 0.40
TSHR P16473 3/20 0.40
MAPT P10636 6/20 0.39
NPSR1 Q6W5P4 2/20 0.39
LMNA P02545 1/20 0.39
HPGD P15428 1/20 0.39
ME3 Q16798 1/20 0.39
EPHX2 P34913 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
SCD O00767 1/20 0.38
USP2 O75604 1/20 0.38
HTT P42858 1/20 0.38
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
TP53 P04637 1/20 0.37
MCL1 Q07820 1/20 0.37
CNR1 P21554 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5535585 0.86 GAA (0.53) GAAKDM4EALDH1A1POLBTSHR
SCHEMBL5536338 0.83 KMT2A (0.49) GAAKDM4EALDH1A1POLBMAPT
SCHEMBL5538936 0.83 MEN1 (0.44) GAAKDM4EALDH1A1POLBMAPT
SCHEMBL5544308 0.82 SCD (0.57) GAAKDM4EPOLBMAPTEPHX2
SCHEMBL5541081 0.80 SCD (0.46) GAAKDM4ETSHRMAPTNPSR1
SCHEMBL5544169 0.80 DRD2 (0.51) GAAKDM4EALDH1A1TSHRMAPT
SCHEMBL5537487 0.79 DDB1 (0.46) GAAEPHX2SCD
SCHEMBL5534878 0.79 ME3 (0.47) ALDH1A1POLBMAPTME3EPHX2
SCHEMBL5546298 0.78 HPGD (0.43) GAAALDH1A1POLBMAPTLMNA
SCHEMBL5543879 0.78 KMT2A (0.40) GAAKDM4EALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 GAA 4165/4885KDM4E 4854/4885ALDH1A1 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.